Nonmyeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of Hematologic Disorders

NCT00533923 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

25

Enrollment

OTHER

Sponsor class

Conditions

AML
ALL
CLL
Myelodysplastic Syndrome
Non-Hodgkin's Lymphoma
Hodgkin's Lymphoma
Multiple Myeloma
Aplastic Anemia
Myeloproliferative Disorder

Interventions

DRUG: Cyclophosphamide; Fludarabine; Cyclosporin; CAMPATH-1H (Alemtuzumab); GM-CSF

Sponsor

Beth Israel Deaconess Medical Center

Collaborators

[object Object]